SAC Capital is maintaining its “buy” call and target price of 37 cents on pharmaceutical distributor Hyphens Pharma.

The price translates to an FY21 Price-to-earnings (P/E) of 17.5x and is expected to give the counter a 23.3% upside from its 30 cent price, analyst Tracy Lim writes in a Aug 24 report.

Her move follows the company’s revenue for 1HFY21 ended June which was “in line with our forecasts”.


To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook